title: BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.
authors: Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors: Roxana S
authors: RS
authors: Dronca
authors: Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors: Aaron S
authors: AS
authors: Mansfield
authors: Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
authors: Sean S
authors: SS
authors: Park
authors: Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.|Department of Urology, Mayo Clinic, Rochester, MN, USA.
authors: Haidong
authors: H
authors: Dong
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000072224:Bcl-2-Like Protein 11 / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D000072224:Bcl-2-Like Protein 11; D014408:Biomarkers, Tumor; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
keywords: Bim; PD-1; PD-L1; T cell; immunotherapy; melanoma